Boston Scientific Corp., Natick, Mass., closed its $27 billion purchase of cardiac devicemaker Guidant Corp., Indianapolis, a day after receiving Federal Trade Commission approval. Boston Scientific had hoped to close the deal March 31 but did not receive FTC approval until Thursday. The company will pay shareholders an additional $95 million in interest as a result of the delay. Boston Scientific also completed its $4.1 billion sale of Guidant's vascular business to Abbott Laboratories, Abbott Park, Ill. The divestiture was required for FTC approval. Boston Scientific beat out Johnson & Johnson in a bidding war for Guidant in January. -- by Joseph Mantone
Boston Scientific completes Guidant acquisition
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.